Skip to main content

Ctl-mediated protection from HIV-1 infection in a high-risk cohort in Tanzania: persistent seronegativity, persistent single-subtype infection, and cross-subtype super-infection

Objective

Cytotoxic T-lymphocytes will be a primary effector in any successful HIV-1 vaccine. Knowledge of the protective CTL epitopes and their cross-subtype effectiveness is incomplete. The study proposes to use the setting of natural infection in individuals multiply exposed to HIV subtypes A, C, and D to gain understanding of a protective CTL response. From a high-risk cohort in Tanzania 3 groups will be identified: persistently seronegative, persistently infected with a single HIV subtype or recombinant, and super infected with a second subtype. CTL ELISPOT and epitope mapping, viral load and diversity, HLA typing, and MHA, a new sub-typing tool, will be employed. This study will be the first to define the CTL response capable of protecting from new HIV infections in persistent seronegatives and, in the same population and setting, to identify the flawed CTL responses that permit super infection of already infected individuals.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

LUDWIG-MAXIMILIANS UNIVERSITY OF MUNICH
Address
5,Leopoldstrasse 5
80802 Muenchen
Germany

Participants (4)

NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES
South Africa
Address

2131 Johannesburg
NATIONAL PUBLIC HEALTH INSTITUTE
Finland
Address
Mannerheimintie 16
00300 Helsinki
REGIONAL MEDICAL OFFICE OF THE MINISTRY OF HEALTH OF TANZANIA
Tanzania
Address

Mbeya
UNIVERSITY OF CAPE TOWN
South Africa
Address
Anzio Road
7925 Observatory, Cape Town